Cytosorbents Corporation is a medical technology company that focuses on developing innovative therapeutic solutions for critical care and cardiovascular patients. Their flagship product, CytoSorb, is a blood purification device designed to remove cytokines and other harmful substances from the bloodstream during severe illnesses, such as sepsis or acute respiratory distress syndrome. The company is dedicated to advancing treatment options that improve patient outcomes and reduce healthcare costs through its cutting-edge technology, which aims to enhance the management of life-threatening conditions in hospital settings.
CytoSorbents shares are trading higher by 20% during Tuesday's session. The company entered into a new $20 million credit facility with Avenue Capital Group.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.27% to 37,758.26 while the NASDAQ rose 0.17% to 15,124.90. The S&P 500 also rose, gaining, 0.23% to 4,792.56.
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points on Thursday. The Dow traded up 0.14% to 37,708.15 while the NASDAQ rose 0.19% to 15,127.17. The S&P 500 also rose, gaining, 0.14% to 4,788.28.
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.14% to 37,708.72 while the NASDAQ rose 0.15% to 15,122.12. The S&P 500 also rose, gaining, 0.18% to 4,790.25.
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the pivotal U.S.
